Chen S, Chen Y. Comment on: “Isotretinoin exposure and risk of inflammatory bowel disease: a systematic review with meta-analysis and trial sequential analysis”. Am J Clin Dermatol. 2023. https://doi.org/10.1007/s40257-023-00802-7.

Yu CL, Chou PY, Liang CS, Chiang LH, Wang TY, Tu YK, et al. Isotretinoin exposure and risk of inflammatory bowel disease: a systematic review with meta-analysis and trial sequential analysis. Am J Clin Dermatol. 2023. https://doi.org/10.1007/s40257-023-00765-9 (Online ahead of print).

Sivaraman S, Rashtak S, Sivaraman S, Scherr R, Baron H, Stone C. Risk of inflammatory bowel disease from isotretinoin: a case–control study. Am J Gastroenterol. 2014;109:S506.

Article  Google Scholar 

Taylor MT, Margolis DJ, Kwatra SG, Barbieri JS. A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease. J Am Acad Dermatol. 2023;88(4):841–7.

Article  CAS  PubMed  Google Scholar 

Crowther M, Lim W, Crowther MA. Systematic review and meta-analysis methodology. Blood. 2010;116(17):3140–6.

Article  CAS  PubMed  Google Scholar 

Kridin K, Ludwig RJ. Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: a large-scale global study. J Am Acad Dermatol. 2023;88(4):824–30.

Article  CAS  PubMed  Google Scholar 

VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. Biometrics. 2020;76(3):746–52.

Article  PubMed  Google Scholar 

Zhao Y, Guyatt G, Gao Y, Hao Q, Abdullah R, Basmaji J, et al. Living alone and all-cause mortality in community-dwelling adults: a systematic review and meta-analysis. EClinicalMedicine. 2022;54: 101677.

Article  PubMed  PubMed Central  Google Scholar 

Shor E, Roelfs D, Vang ZM. The “Hispanic mortality paradox” revisited: meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants’ mortality. Soc Sci Med. 2017;186:20–33.

Article  PubMed  Google Scholar 

Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690–1.

Article  CAS  PubMed  Google Scholar 

Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol. 2013;133(4):907–12.

Article  CAS  PubMed  Google Scholar 

Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin exposure and risk of inflammatory bowel disease. JAMA Dermatol. 2014;150(12):1322–6.

Article  PubMed  Google Scholar 

Lee SY, Jamal MM, Nguyen ET, Bechtold ML, Nguyen DL. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(2):210–6.

Article  PubMed  Google Scholar 

Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case–control study. Am J Gastroenterol. 2009;104(11):2774–8.

Article  CAS  PubMed  Google Scholar